119 related articles for article (PubMed ID: 4727918)
21. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
Logue GL; Rosse WF; Adams JP
J Clin Invest; 1973 May; 52(5):1129-37. PubMed ID: 4700488
[TBL] [Abstract][Full Text] [Related]
22. Membrane-bound hemagglutinin mediates antibody and complement-dependent lysis of influenza virus-treated human platelets in autologous serum.
Kazatchkine MD; Lambré CR; Kieffer N; Maillet F; Nurden AT
J Clin Invest; 1984 Sep; 74(3):976-84. PubMed ID: 6470149
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets.
Dixon RH; Rosse WF
J Clin Invest; 1977 Feb; 59(2):360-8. PubMed ID: 833281
[TBL] [Abstract][Full Text] [Related]
24. The association of respiratory infection, recurrent hematuria, and focal glomerulonephritis with activation of the complement system in the cold.
Day NK; Geiger H; McLean R; Resnick J; Michael A; Good RA
J Clin Invest; 1973 Jul; 52(7):1698-706. PubMed ID: 4198109
[TBL] [Abstract][Full Text] [Related]
25. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
Gyongyossy-Issa MI; McLeod E; Devine DV
J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
[TBL] [Abstract][Full Text] [Related]
26. Disseminated intravascular coagulation and renal failure: Production in the monkey with autologous red blood cell stroma.
Birndorf NI; Lopas H; Robboy SJ
Lab Invest; 1971 Oct; 25(4):314-9. PubMed ID: 5000483
[No Abstract] [Full Text] [Related]
27. A role for complement receptor-like molecules in iron acquisition by Candida albicans.
Moors MA; Stull TL; Blank KJ; Buckley HR; Mosser DM
J Exp Med; 1992 Jun; 175(6):1643-51. PubMed ID: 1588285
[TBL] [Abstract][Full Text] [Related]
28. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.
Fearon DT; Austen KF; Ruddy S
J Exp Med; 1973 Dec; 138(6):1305-13. PubMed ID: 4202731
[TBL] [Abstract][Full Text] [Related]
29. Activation of the alternative (properdin) pathway by divalent cations.
Lew FT; Yukiyama Y; Waks HS; Osler AG
J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
[TBL] [Abstract][Full Text] [Related]
30. Complement activation and the toxicity of stroma-free hemoglobin solutions in primates.
Feola M; Simoni J; Dobke M; Canizaro PC
Circ Shock; 1988 Aug; 25(4):275-90. PubMed ID: 3168173
[TBL] [Abstract][Full Text] [Related]
31. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
32. The alternate complement pathway in inflammatory bowel disease. Quantitation of the C3 proactivator (factor B) protein.
Feinstein PA; Kaplan SR; Thayer WR
Gastroenterology; 1976 Feb; 70(2):181-5. PubMed ID: 2509
[TBL] [Abstract][Full Text] [Related]
33. Interactions of oligochitosan with blood components.
Sun T; Guo X; Zhong R; Ma L; Li H; Gu Z; Guan J; Tan H; You C; Tian M
Int J Biol Macromol; 2019 Mar; 124():304-313. PubMed ID: 30445093
[TBL] [Abstract][Full Text] [Related]
34. The inflammatory effects of TNF-α and complement component 3 on coagulation.
Page MJ; Bester J; Pretorius E
Sci Rep; 2018 Jan; 8(1):1812. PubMed ID: 29379088
[TBL] [Abstract][Full Text] [Related]
35. Human platelet-initiated formation and uptake of the C5-9 complex of human complement.
Zimmerman TS; Kolb WP
J Clin Invest; 1976 Jan; 57(1):203-11. PubMed ID: 812888
[TBL] [Abstract][Full Text] [Related]
36. The alternative pathway of complement activation in the neonate.
Feinstein PA; Kaplan SR
Pediatr Res; 1975 Oct; 9(10):803-6. PubMed ID: 1103071
[TBL] [Abstract][Full Text] [Related]
37. The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes.
Wands JR; Mann E; Alpert E; Isselbacher KJ
J Clin Invest; 1975 May; 55(5):930-6. PubMed ID: 1123429
[TBL] [Abstract][Full Text] [Related]
38. Inactivator of the third component of complement as an inhibitor in the properdin pathway.
Alper CA; Rosen FS; Lachmann PJ
Proc Natl Acad Sci U S A; 1972 Oct; 69(10):2910-3. PubMed ID: 4507613
[TBL] [Abstract][Full Text] [Related]
39. Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury.
Polley MJ; Nachman RL
J Exp Med; 1975 Jun; 141(6):1261-8. PubMed ID: 805209
[TBL] [Abstract][Full Text] [Related]
40. Hemolysis of normal human erythrocytes by autologous serum complement.
Kitamura H; Nagano A; Kitano E
Int Arch Allergy Immunol; 1993; 100(3):209-14. PubMed ID: 8453307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
